After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
Transcript
What services will stay online for patients on specialty drugs in the post-pandemic world?
Well, I think under the commercial benefit, the ability to have a homebound administration is really critical. Do we see that homebound administration always be self-administered meaning by the patient, or will we see, you know, caregiver administration or home administration via IV [intravenous], but coordinated by say a specialty pharmacy? I think there is a real opportunity there for that to stick or remain.
Does that extend over into government books of business where those products are usually physician administered? I think that remains to be seen as to how that will continue to evolve or expand post the PHE [public health emergency]. But certainly, flexibility of choice and the beneficiary having that choice could line up with a plan of interest in more preferred or mandated step therapy of products that are self-administered versus those that are physician administered or those that might be administered in a hospital outpatient setting.
So, I think those incentives start to line up the patient might not want to ambulate, the plan may want to have that patient managed in a less acute setting of care. Does that lead to more self administer? Probably so. Does that lead to more pharmacy-coordinated physician or nurse administered in home? Probably so as well.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More